Background: Faecal calprotectin levels correlate with inflammation in inflammatory bowel disease. We evaluated the role of faecal calprotectin after anti-Tumour Necrosis Factor α induction in inflammatory bowel disease patients to predict therapeutic effect at one year. Methods: Faecal calprotectin levels were measured in stools of 63 patients before and after induction of anti-Tumour Necrosis Factor α therapy. Clinical activity, measured by clinical indices, was assessed before and after biologic treatment. Clinical responders after induction were included in the study and colonoscopy was performed before and after one year of treatment to assess mucosal healing. Results: 63 patients (44 Crohn's disease, 19 ulcerative colitis) were prospectively included (41.2% males, mean age at diagnosis 33 years). A sustained clinical response during the first year was observed in 57% of patients; median faecal calprotectin was 106. μg/g after induction versus 308. μg/g pre-induction (. p<. 0.0001). Post-induction faecal calprotectin was significantly lower in responders versus non-responders (. p=. 0.0002). Post-induction faecal calprotectin had 83% sensitivity and 74% specificity (cut-off ≤168. μg/g) for predicting a sustained clinical response at one year (. p=. 0.0001); also, sensitivity was 79% and specificity 57% (cut-off ≤121. μg/g) for predicting mucosal healing (. p=. 0.0001). Conclusions: In inflammatory bowel disease faecal calprotectin assay after anti-Tumour Necrosis Factor α induction can be used as a marker to predict sustained clinical response and mucosal healing at one year.

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year

Felice C.;
2014

Abstract

Background: Faecal calprotectin levels correlate with inflammation in inflammatory bowel disease. We evaluated the role of faecal calprotectin after anti-Tumour Necrosis Factor α induction in inflammatory bowel disease patients to predict therapeutic effect at one year. Methods: Faecal calprotectin levels were measured in stools of 63 patients before and after induction of anti-Tumour Necrosis Factor α therapy. Clinical activity, measured by clinical indices, was assessed before and after biologic treatment. Clinical responders after induction were included in the study and colonoscopy was performed before and after one year of treatment to assess mucosal healing. Results: 63 patients (44 Crohn's disease, 19 ulcerative colitis) were prospectively included (41.2% males, mean age at diagnosis 33 years). A sustained clinical response during the first year was observed in 57% of patients; median faecal calprotectin was 106. μg/g after induction versus 308. μg/g pre-induction (. p<. 0.0001). Post-induction faecal calprotectin was significantly lower in responders versus non-responders (. p=. 0.0002). Post-induction faecal calprotectin had 83% sensitivity and 74% specificity (cut-off ≤168. μg/g) for predicting a sustained clinical response at one year (. p=. 0.0001); also, sensitivity was 79% and specificity 57% (cut-off ≤121. μg/g) for predicting mucosal healing (. p=. 0.0001). Conclusions: In inflammatory bowel disease faecal calprotectin assay after anti-Tumour Necrosis Factor α induction can be used as a marker to predict sustained clinical response and mucosal healing at one year.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3447795
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 58
social impact